06/04/2025
Yesterday, I had the honor of representing ERDC - Eosinophilic & Rare Disease Cooperative and the broader rare disease community at a standing-room-only Congressional briefing on tariffs and their impact on the healthcare supply chain. Over 70 attendees—mostly legislative staff—joined to better understand what’s at stake.
💡 Did you know it takes 24 individual medical items to safely deliver a single infusion? Now, Congressional staff do too—thanks to this important conversation.
Millions of Americans with chronic and rare conditions rely on timely access to infusions, devices, and treatments. Tariffs on pharmaceuticals and medical supplies threaten to delay care, disrupt treatment, and harm lives. This is preventable—and action is needed.
Grateful to Center Forward for the invitation and to my fellow panelists from Biotech Innovation Organization (Hilary Stiss), National Association of Manufacturers - NAM, and Healthcare Supply Chain Association for an engaging and urgent dialogue.
This issue affects all of us—patients, providers, manufacturers, and lawmakers alike. Let’s keep the pressure on to ensure healthcare remains accessible, uninterrupted, and affordable.